Data sources for drug utilization research in Latin American countries-A cross-national study: DASDUR-LATAM study.

Autor: Lopes LC; Pharmaceutical Science Graduate Course, University of Sorocaba, Sorocaba, Brazil., Salas M; Epidemiology, Cardiovascular, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Inc., Basking Ridge, USA.; CCEB/CPeRT, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA., Osorio-de-Castro CGS; Department of Medicines Policy and Pharmaceutical Services, Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Leal LF; Department of Epidemiology Biostatistics and Occupational Health, McGill University/Centre for Clinical Epidemiology - Lady Davis Institute, Montreal, Canada., Doubova SV; Epidemiology and Health Services Research Unit CMN Siglo XXI, Mexican Institute of Social Security, Mexico City, Mexico., Cañás M; Institute of Health Sciences, Arturo Jauretche National University, Florencio Varela, Argentina.; Federación Médica de la Provincia de Buenos Aires, FEMEBA, La Plata, Argentina., Dreser A; Centre for Health Systems Research, National Institute of Public Health, Cuernavaca, Mexico., Acosta A; Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Naturales, Universidad ICESI, Cali, Colombia., Baldoni AO; Pharmaceutical Science Course, Federal University of São João Del-Rei, Divinópolis, Brazil., de Cássia Bergamaschi C; Pharmaceutical Science Graduate Course, University of Sorocaba, Sorocaba, Brazil., Mota DM; Fifth Board of Directors, Brazilian Health Regulatory Agency - ANVISA, Brasilia, Brazil., Gómez-Galicia DL; PITC - Pharmacy of Faculty, Autonomous University of the State of Morelos, Cuernavaca, Mexico., Sepúlveda-Viveros D; School of Medicine, Autonomous University of Chile, Santiago, Chile., Delgado EN; Public Health, Self-employed, Managua, Nicaragua., da Costa Lima E; School of Pharmacy, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Chandia FV; Health Technology Assessment Unit, Pontifical Catholic University of Chile, Santiago, Chile., Ferre F; School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil., Marin GH; Faculty of Medicine, National University of La Plata - CONICET, La Plata, Argentina., Olmos I; Unit of Clinical Pharmacology - Vilardebó Hospital, ASSE - State Health Services Administration, Montevidéu, Uruguay., Zimmermann IR; Department of Public Health, University of Brasilia, Brasilia, Brazil., Fulone I; Pharmaceutical Science Graduate Course, University of Sorocaba, Sorocaba, Brazil., Roldán-Saelzer J; Pharmacovigilance Subdepartment, of the Department National Medicines Agency, Institute of Public Health of Chile, Santiago, Chile., Sánchez-Salgado JC; Scientific Department, Hypermedic MX, Mexico City, Mexico., Castro-Pastrana LI; Department of Chemical and Biological Sciences, University of the Americas Puebla, Cholula, Mexico., de Souza LJC; Research and Development, Oswaldo Cruz Foundation (Ministry of Health), Brasilia, Brazil., Beltrán MM; Pharmaceutical Science, National University of Colombia, Bogota, Colombia., Silva MT; Pharmaceutical Science Graduate Course, University of Sorocaba, Sorocaba, Brazil., Mena MB; Faculty of Medical Sciences, Central University of Ecuador, Quito, Ecuador., de França Fonteles MM; Technological Development and Innovation in Medicines Graduate Course, Federal University of Ceara, Fortaleza, Brazil., Urtasun MA; Institute of Health Sciences, Arturo Jauretche National University, Florencio Varela, Argentina.; Federación Médica de la Provincia de Buenos Aires, FEMEBA, La Plata, Argentina., Tarapués M; Faculty of Medical Sciences, Central University of Ecuador, Quito, Ecuador., Hernández PG; Humanistic Organization for Social Change, HIVOS, Quito, Ecuador., Medero N; Unit of Clinical Pharmacology - Vilardebó Hospital, ASSE - State Health Services Administration, Montevidéu, Uruguay., Herrera-Comoglio R; School of Medical Sciences, National University of Cordoba, Córdoba, Argentina., Barberato-Filho S; Pharmaceutical Science Graduate Course, University of Sorocaba, Sorocaba, Brazil., Galvão TF; School of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil., Luiza VL; Department of Medicines Policy and Pharmaceutical Services, Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Santa-Ana-Tellez Y; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht, Netherlands., Rodríguez-Tanta Y; Institute of Health and Technology Assessment and Research, ESSALUD - Social Security of Peru, Lima, Peru., Elseviers M; Centre for Research and Innovation in Care, University of Antwerp, Antwerp, Belgium.; Department of Clinical Pharmacology, University of Ghent, Belgium, Centre for Research and Innovation in Care, University of Antwerp, Antwerpen, Belgium.
Jazyk: angličtina
Zdroj: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2022 Mar; Vol. 31 (3), pp. 343-352. Date of Electronic Publication: 2022 Jan 13.
DOI: 10.1002/pds.5404
Abstrakt: Purpose: Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step for conducting DUR. However, documents that systematize these data sources in Latin American (LatAm) countries are not known. We compiled the potential data sources for DUR in the LatAm region.
Methods: A network of DUR experts from nine LatAm countries was assembled and experts conducted: (i) a website search of the government, academic, and private health institutions; (ii) screening of eligible data sources, and (iii) liaising with national experts in pharmacoepidemiology (via an online survey). The data sources were characterized by accessibility, geographic granularity, setting, sector of the data, sources and type of the data. Descriptive analyses were performed.
Results: We identified 125 data sources for DUR in nine LatAm countries. Thirty-eight (30%) of them were publicly and conveniently available; 89 (71%) were accessible with limitations, and 18 (14%) were not accessible or lacked clear rules for data access. From the 125 data sources, 76 (61%) were from the public sector only; 46 (37%) were from pharmacy records; 43 (34%) came from ambulatory settings and; 85 (68%) gave access to individual patient-level data.
Conclusions: Although multiple sources for DUR are available in LatAm countries, the accessibility is a major challenge. The procedures for accessing DUR data should be transparent, feasible, affordable, and protocol-driven. This inventory could permit a comparison of drug utilization between countries identifying potential medication-related problems that need further exploration.
(© 2021 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: